Literature DB >> 20490454

DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes.

A Hoverfelt1, R Sallinen, J M Söderlund, C Forsblom, K Pettersson-Fernholm, M Parkkonen, P-H Groop, M Wessman.   

Abstract

AIMS/HYPOTHESIS: The AGE receptors 1, 2 and 3, which are encoded by DDOST, PRKCSH and LGALS3, respectively, may be involved in the pathogenesis of diabetic complications. We sought to find out whether these genes are associated with diabetic nephropathy, cardiovascular disease and type 1 diabetes or related quantitative traits.
METHODS: Using the Tagger program, we selected 28 single nucleotide polymorphisms (SNPs) based on the HapMap Centre d'Etude du Polymorphisme (Utah residents with northern and western European ancestry) data. The SNPs were genotyped in 2,719 Finnish patients with type 1 diabetes and tested for association with diabetic nephropathy (821 cases, 1,060 controls), cardiovascular disease and related quantitative traits. For association analysis with type 1 diabetes, 703 non-diabetic control participants were genotyped.
RESULTS: We found evidence of genotype association between diabetic nephropathy and the SNPs rs2170336 in DDOST (p = 0.03), rs311788 in PRKCSH (p = 0.04) and rs311778 in PRKCSH (p = 0.02). However, these associations did not reach the significance limit of 0.0008 adjusted for multiple testing. None of the DDOST, PRKCSH or LGALS3 SNPs were associated with quantitative traits related to diabetic nephropathy, including AER and estimated GFR. No associations were found between the SNPs and cardiovascular disease, blood pressure, serum lipid levels or type 1 diabetes. CONCLUSIONS/
INTERPRETATION: The common SNPs tested in DDOST, PRKCSH and LGALS3 do not seem to be associated with diabetic micro- or macrovascular complications or with type 1 diabetes in Finnish patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490454     DOI: 10.1007/s00125-010-1771-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  13 in total

1.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Authors:  Changyong Lu; John Cijiang He; Weijing Cai; Huixian Liu; Li Zhu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

2.  Evaluation of HapMap data in six populations of European descent.

Authors:  Per E Lundmark; Ulrika Liljedahl; Dorret I Boomsma; Heikki Mannila; Nicholas G Martin; Aarno Palotie; Leena Peltonen; Markus Perola; Tim D Spector; Ann-Christine Syvänen
Journal:  Eur J Hum Genet       Date:  2008-04-09       Impact factor: 4.246

3.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE.

Authors:  C J He; T Koschinsky; C Buenting; H Vlassara
Journal:  Mol Med       Date:  2001-03       Impact factor: 6.354

5.  Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients.

Authors:  G Prevost; I Fajardy; C Besmond; B Balkau; J Tichet; P Fontaine; P M Danze; M Marre
Journal:  Diabetes Metab       Date:  2005-02       Impact factor: 6.041

6.  The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.

Authors:  E Lindholm; E Bakhtadze; M Sjögren; C M Cilio; E Agardh; L Groop; C-D Agardh
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

Review 7.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

8.  The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.

Authors:  Kim Pettersson-Fernholm; Carol Forsblom; Barry I Hudson; Markus Perola; Peter J Grant; Per-Henrik Groop
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

Review 9.  Autoimmune diseases: insights from genome-wide association studies.

Authors:  Guillaume Lettre; John D Rioux
Journal:  Hum Mol Genet       Date:  2008-10-15       Impact factor: 6.150

10.  Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.

Authors:  Markku Saraheimo; Carol Forsblom; Lena Thorn; Johan Wadén; Milla Rosengård-Bärlund; Outi Heikkilä; Kustaa Hietala; Daniel Gordin; Jan Frystyk; Allan Flyvbjerg; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2008-03-17       Impact factor: 19.112

View more
  4 in total

Review 1.  Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Authors:  Aowen Zhuang; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

Review 2.  Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot.

Authors:  Yanhua Li; Tian Li; Zhiguang Zhou; Yang Xiao
Journal:  Rev Endocr Metab Disord       Date:  2022-01-27       Impact factor: 9.306

3.  PRKCSH Alternative Splicing Involves in Silica-Induced Expression of Epithelial-Mesenchymal Transition Markers and Cell Proliferation.

Authors:  Ruixue Huang; Xiaodan Liu; He Li; Huacheng Ning; Ping-Kun Zhou
Journal:  Dose Response       Date:  2020-05-08       Impact factor: 2.658

4.  Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Authors:  Aowen Zhuang; Felicia Y T Yap; Domenica McCarthy; Chris Leung; Karly C Sourris; Sally A Penfold; Vicki Thallas-Bonke; Melinda T Coughlan; Benjamin L Schulz; Josephine M Forbes
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.